Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Armstrong Discusses AR-V7 Testing in Prostate Cancer

Andrew J. Armstrong, MD
Published: Tuesday, Oct 24, 2017



Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Currently, there are 2 lead candidates for the AR-V7 test—the Epic Sciences AR-V7 Test from Genomic Health, and a Johns Hopkins assay that is based on RNA.

Neither of these studies are FDA approved, but both are undergoing prospective validation.
 


Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Currently, there are 2 lead candidates for the AR-V7 test—the Epic Sciences AR-V7 Test from Genomic Health, and a Johns Hopkins assay that is based on RNA.

Neither of these studies are FDA approved, but both are undergoing prospective validation.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x